

**AMENDMENTS TO THE CLAIMS:**

The following Listing of Claims replaces all prior versions, and listings, of claims.

**LISTING OF CLAIMS**

Claims 1-74 (Cancelled)

Claim [73] 75 (Currently Amended) A compound which comprises a therapeutic polypeptide linked to an albumin binding residue via a hydrophilic spacer.

Claim [74] 76 (Currently Amended) A compound which comprises a therapeutic polypeptide linked to an albumin binding residue via a hydrophilic spacer  $-(CH_2)_lD[(CH_2)_nE]_m(CH_2)_pQ_q-$ , wherein l, m and n independently are 1-20 and p is 0-10, Q is  $-Z-(CH_2)_lD[(CH_2)_nG]_m(CH_2)_p-$ , q is an integer in the range from 0 to 5, each D, E, and G independently are selected from  $-O-$ ,  $-NR^3-$ ,  $-N(COR^4)-$ ,  $-PR^5(O)-$ , and  $-P(OR^6)(O)-$ , wherein  $R^3$ ,  $R^4$ ,  $R^5$ , and  $R^6$  independently represent hydrogen or  $C_{1-6}$ -alkyl, Z is selected from  $-C(O)NH-$ ,  $-C(O)NHCH_2-$ ,  $-OC(O)NH-$ ,  $-C(O)NHCH_2CH_2-$ ,  $-C(O)CH_2-$ ,  $-C(O)CH=CH-$ ,  $-(CH_2)_s-$ ,  $-C(O)-$ ,  $-C(O)O-$  or  $-NHC(O)-$ , wherein s is 0 or 1 or a pharmaceutically acceptable salt or prodrug thereof.

Claim [75] 77 (Currently Amended) A compound according to claim [74] 76, which has formula (I) :



wherein

A is an albumin binding residue,

B is a hydrophilic spacer being  $-(CH_2)_lD[(CH_2)_nE]_m(CH_2)_pQ_q-$ , wherein

l, m and n independently are 1-20 and p is 0-10,

Q is  $-Z-(CH_2)_lD[(CH_2)_nG]_m(CH_2)_p-$ ,

q is an integer in the range from 0 to 5,

each D, E, and G independently are selected from  $-O-$ ,  $-NR^3-$ ,  $-N(COR^4)-$ ,  $-PR^5(O)-$ , and  $-P(OR^6)(O)-$ , wherein  $R^3$ ,  $R^4$ ,  $R^5$ , and  $R^6$  independently represent hydrogen or  $C_{1-6}$ -alkyl,

Z is selected from -C(O)NH-, -C(O)NHCH<sub>2</sub>-, -OC(O)NH -, -C(O)NHCH<sub>2</sub>CH<sub>2</sub>-, -C(O)CH<sub>2</sub>-, -C(O)CH=CH-, -(CH<sub>2</sub>)<sub>s</sub>-, -C(O)-, -C(O)O- or -NHC(O)-, wherein s is 0 or 1,

Y is a chemical group linking B and the therapeutic agent, and

W is a chemical group linking A and B.

Claim [76] 78 (Currently Amended) A compound according to claim [74] 76, which has formula (II)



wherein

A and A' are albumin binding residues,

B and B' are hydrophilic spacers independently selected from -(CH<sub>2</sub>)<sub>l</sub>D [(CH<sub>2</sub>)<sub>n</sub>E]<sub>m</sub>(CH<sub>2</sub>)<sub>p</sub>-Q<sub>q</sub>-, wherein

l, m and n independently are 1-20 and p is 0-10,

Q is -Z-(CH<sub>2</sub>)<sub>l</sub>D[(CH<sub>2</sub>)<sub>n</sub>G]<sub>m</sub>(CH<sub>2</sub>)<sub>p</sub>-,

q is an integer in the range from 0 to 5,

each D, E, and G independently are selected from -O-, -NR<sup>3</sup>-, -N(COR<sup>4</sup>)-, -PR<sup>5</sup>(O)-, and -P(OR<sup>6</sup>)(O)-, wherein R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, and R<sup>6</sup> independently represent hydrogen or C<sub>1-6</sub>-alkyl,

Z is selected from -C(O)NH-, -C(O)NHCH<sub>2</sub>-, -OC(O)NH -, -C(O)NHCH<sub>2</sub>CH<sub>2</sub>-, -C(O)CH<sub>2</sub>-, -C(O)CH=CH-, -(CH<sub>2</sub>)<sub>s</sub>-, -C(O)-, -C(O)O- or -NHC(O)-, wherein s is 0 or 1,

Y is a chemical group linking B and the therapeutic agent, and

Y' is a chemical group linking B' and the therapeutic agent, and

W is a chemical group linking A and B, and

W' is a chemical group linking A' and B'.

Claim [77] 79 (Currently Amended) A compound according to claim [76] 78, wherein Y' is selected from the group consisting of -C(O)NH-, -NHC(O)-, -C(O)NHCH<sub>2</sub>-, -CH<sub>2</sub>NHC(O)-, -OC(O)NH -, -NHC(O)O-, -C(O)NHCH<sub>2</sub>-, CH<sub>2</sub>NHC(O)-, -C(O)CH<sub>2</sub>-, -CH<sub>2</sub>C(O)-, -C(O)CH=CH-, -CH=CHC(O)-, -(CH<sub>2</sub>)<sub>s</sub>-, -C(O)-, -C(O)O-, -OC(O)-, -NHC(O)- and -C(O)NH-, wherein s is 0 or 1.

Claim [78] 80 (Currently Amended) A compound according to claim [76] 78, wherein W' is selected from the group consisting of -C(O)NH-, -NHC(O)-, -C(O)NHCH<sub>2</sub>-, -CH<sub>2</sub>NHC(O)-, -OC(O)NH -, -

NHC(O)O-, -C(O)CH<sub>2</sub>-, -CH<sub>2</sub>C(O)-, -C(O)CH=CH-, -CH=CHC(O)-, -(CH<sub>2</sub>)<sub>s</sub>-, -C(O)-, -C(O)O-, -OC(O)-, -NHC(O)- and -C(O)NH-, wherein s is 0 or 1.

Claim [79] 81 (Currently Amended) A compound according to claim [74] 76, which has formula (III)



wherein

A and A' are albumin binding residues,

B is a hydrophilic spacer selected from -(CH<sub>2</sub>)<sub>l</sub>D[(CH<sub>2</sub>)<sub>n</sub>E]<sub>m</sub>(CH<sub>2</sub>)<sub>p</sub>-Q<sub>q</sub>- wherein

l, m and n independently are 1-20 and p is 0-10,

Q is -Z-(CH<sub>2</sub>)<sub>l</sub>D[(CH<sub>2</sub>)<sub>n</sub>G]<sub>m</sub>(CH<sub>2</sub>)<sub>p</sub>-,

q is an integer in the range from 0 to 5,


each D, E, and G are independently selected from -O-, -NR<sup>3</sup>-, -N(COR<sup>4</sup>)-, -PR<sup>5</sup>(O)-, and -P(OR<sup>6</sup>)(O)-, wherein R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, and R<sup>6</sup> independently represent hydrogen or C<sub>1-6</sub>-alkyl,

Z is selected from -C(O)NH-, -C(O)NHCH<sub>2</sub>-, -OC(O)NH-, -C(O)NHCH<sub>2</sub>CH<sub>2</sub>-, -C(O)CH<sub>2</sub>-, -C(O)CH=CH-, -(CH<sub>2</sub>)<sub>s</sub>-, -C(O)-, -C(O)O- or -NHC(O)-, wherein s is 0 or 1,

Y is a chemical group linking B and the therapeutic agent, and

W'' is a chemical group linking B with A and A'.

Claim [80] 82 (Currently Amended) A compound according to claim [79] 81, wherein W'' is selected from the group consisting of



wherein s is 0, 1 or 2.

Claim [81] 83 (Currently Amended) A compound according to claim [75] 77, wherein Y is selected from the group consisting of -C(O)NH-, -NHC(O)-, -C(O)NHCH<sub>2</sub>-, -CH<sub>2</sub>NHC(O)-, -OC(O)NH-, -NHC(O)O-, -C(O)NHCH<sub>2</sub>-, CH<sub>2</sub>NHC(O)-, -C(O)CH<sub>2</sub>-, -CH<sub>2</sub>C(O)-, -C(O)CH=CH-, -CH=CHC(O)-, -(CH<sub>2</sub>)<sub>s</sub>-, -C(O)-, -C(O)O-, -OC(O)-, -NHC(O)- and -C(O)NH-, wherein s is 0 or 1.

Claim [82] 84 (Currently Amended) A compound according to claim [75] 77, wherein W is selected from the group consisting of -C(O)NH-, -NHC(O)-, -C(O)NHCH<sub>2</sub>-, -CH<sub>2</sub>NHC(O)-, -OC(O)NH-, -NHC(O)O-, -C(O)CH<sub>2</sub>-, -CH<sub>2</sub>C(O)-, -C(O)CH=CH-, -CH=CHC(O)-, -(CH<sub>2</sub>)<sub>s</sub>-, -C(O)-, -C(O)O-, -OC(O)-, -NHC(O)- and -C(O)NH-, wherein s is 0 or 1.

Claim [83] 85 (Currently Amended) A compound according to claim [74] 76, wherein l is 1 or 2, n and m are independently 1-10 and p is 0-10.

Claim [84] 86 (Currently Amended) A compound according to claim [74] 76, wherein D is -O-.

Claim [85] 87 (Currently Amended) A compound according to claim [74] 76, wherein E is -O-.

Claim [86] 88 (Currently Amended) A compound according to claim [74] 76, wherein the hydrophilic spacer is

-CH<sub>2</sub>O[(CH<sub>2</sub>)<sub>2</sub>O]<sub>m</sub>(CH<sub>2</sub>)<sub>p</sub>Q<sub>q</sub>-, where m is 1-10, p is 1-3, and Q is -Z-CH<sub>2</sub>O[(CH<sub>2</sub>)<sub>2</sub>O]<sub>m</sub>(CH<sub>2</sub>)<sub>p</sub>-.

Claim [87] 89 (Currently Amended) A compound according to claim [74] 76, wherein q is 0 or 1.

Claim [88] 90 (Currently Amended) A compound according to claim [74] 76, wherein q is 1.

Claim [89] 91 (Currently Amended) A compound according to claim [74] 76, wherein G is -O-.

Claim [90] 92 (Currently Amended) A compound according to claim [74] 76, wherein Z is selected from the group consisting of -C(O)NH-, -C(O)NHCH<sub>2</sub>-, and -OC(O)NH-.

Claim [91] 93 (Currently Amended) A compound according to claim [74] 76, wherein q is 0.

Claim [92] 94 (Currently Amended) A compound according to claim [74] 76, wherein l is 2.

Claim [93] 95 (Currently Amended) A compound according to claim [74] 76, wherein n is 2.






Claim [94] 96 (Currently Amended) A compound according to claim [74] 76, wherein the hydrophilic spacer B is  $-\text{[CH}_2\text{CH}_2\text{O]}_{m+1}(\text{CH}_2)_p\text{Q}_q-$ .


Claim [95] 97 (Currently Amended) A compound according to claim [74] 76, wherein the hydrophilic spacer B is

$-(\text{CH}_2)_l-\text{O}-[(\text{CH}_2)_n-\text{O}]_m-(\text{CH}_2)_p-[\text{C}(\text{O})\text{NH}-(\text{CH}_2)_l-\text{O}-[(\text{CH}_2)_n-\text{O}]_m-(\text{CH}_2)_p]_q-$ ,


where l, m, n, and p independently are 1-5, and q is 0-5.

Claim [96] 98 (Currently Amended) A compound according to claim [75] 77, wherein  $-\text{W}-\text{B}-\text{Y}-$  is selected from the group consisting of





Claim [97] 99 (Currently Amended) A compound according to claim [79] 81, wherein >W''-B-Y- is



Claim [98] 100 (Currently Amended) A compound according to claim [73] 75, wherein the molar weight of said hydrophilic spacer is in the range from 80D to 1000D or in the range from 80D to 300D.

Claim [99] 101 (Currently Amended) A compound according to claim [73] 75, wherein said albumin binding residue is a lipophilic residue.

Claim [100] 102 (Currently Amended) A compound according to claim [73] 75, wherein said albumin binding residue binds non-covalently to albumin.

Claim [101] 103 (Currently Amended) A compound according to claim [73] 75, wherein said albumin binding residue is negatively charged at physiological pH.

Claim [102] 104 (Currently Amended) A compound according to claim [73] 75, wherein said albumin binding residue has a binding affinity towards human serum albumin that is below about 10  $\mu$ M.

Claim [103] 105 (Currently Amended) A compound according to claim [73] 75, wherein said albumin binding residue is selected from a straight chain alkyl group, a branched alkyl group, a group which has an  $\omega$ -carboxylic acid group, a partially or completely hydrogenated cyclopentanophenanthrene skeleton.

Claim [104] 106 (Currently Amended) A compound according to claim [73] 75, wherein said albumin binding residue is a cibacronyl residue.

Claim [105] 107 (Currently Amended) A compound according to claim [73] 75, wherein said albumin binding residue has from 6 to 40 carbon atoms.

Claim [106] 108 (Currently Amended) A compound according to claim [73] 75, wherein said albumin binding residue is a peptide.

Claim [107] 109 (Currently Amended) A compound according to claim [73] 75, wherein the albumin binding residue via spacer and linkers is attached to said therapeutic polypeptide via the  $\epsilon$ -amino group of a lysine residue.

Claim [108] 110 (Currently Amended) A compound according to claim [73] 75, wherein the albumin binding residue via spacer and linkers is attached to said therapeutic polypeptide via a linker to an amino acid residue selected from cysteine, glutamate and aspartate.



Claim [109] 111 (Currently Amended) A compound according to claim [73] 75, wherein said therapeutic polypeptide is a glucagon-like peptide 1 (GLP-1) peptide.

Claim [110] 112 (Currently Amended) A compound according to claim [109] 111, wherein said polypeptide is a GLP-1 peptide comprising the amino acid sequence of the formula (IV):

Xaa<sub>7</sub>-Xaa<sub>8</sub>-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Xaa<sub>16</sub>-Ser-Xaa<sub>18</sub>-Xaa<sub>19</sub>-Xaa<sub>20</sub>-Glu-Xaa<sub>22</sub>-Xaa<sub>23</sub>-Ala-Xaa<sub>25</sub>-  
Xaa<sub>26</sub>-Xaa<sub>27</sub>-Phe-Ile-Xaa<sub>30</sub>-Trp-Leu-Xaa<sub>33</sub>-Xaa<sub>34</sub>-Xaa<sub>35</sub>-Xaa<sub>36</sub>-Xaa<sub>37</sub>-Xaa<sub>38</sub>-Xaa<sub>39</sub>-Xaa<sub>40</sub>-Xaa<sub>41</sub>-Xaa<sub>42</sub>-  
Xaa<sub>43</sub>-Xaa<sub>44</sub>-Xaa<sub>45</sub>-Xaa<sub>46</sub>

Formula (IV) (SEQ ID No: 2)

wherein

Xaa<sub>7</sub> is L-histidine, D-histidine, desamino-histidine, 2-amino-histidine, β-hydroxy-histidine, homohistidine, N<sup>α</sup>-acetyl-histidine, α-fluoromethyl-histidine, α-methyl-histidine, 3-pyridylalanine, 2-pyridylalanine or 4-pyridylalanine;

Xaa<sub>8</sub> is Ala, Gly, Val, Leu, Ile, Lys, Aib, (1-aminocyclopropyl) carboxylic acid, (1-aminocyclobutyl) carboxylic acid, (1-aminocyclopentyl) carboxylic acid, (1-aminocyclohexyl) carboxylic acid, (1-aminocycloheptyl) carboxylic acid, or (1-aminocyclooctyl) carboxylic acid;

Xaa<sub>16</sub> is Val or Leu;

Xaa<sub>18</sub> is Ser, Lys or Arg;

Xaa<sub>19</sub> is Tyr or Gln;

Xaa<sub>20</sub> is Leu or Met;

Xaa<sub>22</sub> is Gly, Glu or Aib;

Xaa<sub>23</sub> is Gln, Glu, Lys or Arg;

Xaa<sub>25</sub> is Ala or Val;

Xaa<sub>26</sub> is Lys, Glu or Arg;

Xaa<sub>27</sub> is Glu or Leu;

Xaa<sub>30</sub> is Ala, Glu or Arg;

Xaa<sub>33</sub> is Val or Lys;

Xaa<sub>34</sub> is Lys, Glu, Asn or Arg;

Xaa<sub>35</sub> is Gly or Aib;

Xaa<sub>36</sub> is Arg, Gly or Lys;



Xaa<sub>37</sub> is Gly, Ala, Glu, Pro, Lys, amide or is absent;

Xaa<sub>38</sub> is Lys, Ser, amide or is absent.

Xaa<sub>39</sub> is Ser, Lys, amide or is absent;

Xaa<sub>40</sub> is Gly, amide or is absent;

Xaa<sub>41</sub> is Ala, amide or is absent;

Xaa<sub>42</sub> is Pro, amide or is absent;

Xaa<sub>43</sub> is Pro, amide or is absent;

Xaa<sub>44</sub> is Pro, amide or is absent;

Xaa<sub>45</sub> is Ser, amide or is absent;

Xaa<sub>46</sub> is amide or is absent ;

provided that if Xaa<sub>38</sub>, Xaa<sub>39</sub>, Xaa<sub>40</sub>, Xaa<sub>41</sub>, Xaa<sub>42</sub>, Xaa<sub>43</sub>, Xaa<sub>44</sub>, Xaa<sub>45</sub> or Xaa<sub>46</sub> is absent then each amino acid residue downstream is also absent.

Claim [111] 113 (Currently Amended) A compound according to claim [110] 112, wherein said polypeptide is a GLP-1 peptide comprising the amino acid sequence of formula (V):

Xaa<sub>7</sub>-Xaa<sub>8</sub>-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Xaa<sub>18</sub>-Tyr-Leu-Glu-Xaa<sub>22</sub>-Xaa<sub>23</sub>-Ala-Ala-Xaa<sub>26</sub>-  
Glu-Phe-Ile-Xaa<sub>30</sub>-Trp-Leu-Val-Xaa<sub>34</sub>-Xaa<sub>35</sub>-Xaa<sub>36</sub>-Xaa<sub>37</sub>-Xaa<sub>38</sub>

Formula (V) (SEQ ID No: 3)

wherein

Xaa<sub>7</sub> is L-histidine, D-histidine, desamino-histidine, 2-amino-histidine,  $\beta$ -hydroxy-histidine, homohistidine, N <sup>$\alpha$</sup> -acetyl-histidine,  $\alpha$ -fluoromethyl-histidine,  $\alpha$ -methyl-histidine, 3-pyridylalanine, 2-pyridylalanine or 4-pyridylalanine;

Xaa<sub>8</sub> is Ala, Gly, Val, Leu, Ile, Lys, Aib, (1-aminocyclopropyl) carboxylic acid, (1-aminocyclobutyl) carboxylic acid, (1-aminocyclopentyl) carboxylic acid, (1-aminocyclohexyl) carboxylic acid, (1-aminocycloheptyl) carboxylic acid, or (1-aminocyclooctyl) carboxylic acid;

Xaa<sub>18</sub> is Ser, Lys or Arg;

Xaa<sub>22</sub> is Gly, Glu or Aib;

Xaa<sub>23</sub> is Gln, Glu, Lys or Arg;

Xaa<sub>26</sub> is Lys, Glu or Arg;

Xaa<sub>30</sub> is Ala, Glu or Arg;

Xaa<sub>34</sub> is Lys, Glu or Arg;

Xaa<sub>35</sub> is Gly or Aib;

Xaa<sub>36</sub> is Arg or Lys;

Xaa<sub>37</sub> is Gly, Ala, Glu or Lys;

Xaa<sub>38</sub> is Lys, amide or is absent.

Claim [112] 114 (Currently Amended) A compound according to claim [109] 111, wherein said GLP-1 peptide is selected from GLP-1(7-35), GLP-1(7-36), GLP-1(7-36)-amide, GLP-1(7-37), GLP-1(7-38), GLP-1(7-39), GLP-1(7-40), GLP-1(7-41) or an analogue thereof.

Claim [113] 115 (Currently Amended) A compound according to claim [109] 111, wherein said GLP-1 peptide comprises no more than ten amino acid residues which have been exchanged, added or deleted as compared to GLP-1(7-37) (SEQ ID No. 1).

Claim [114] 116 (Currently Amended) A compound according to claim [113] 115, wherein said GLP-1 peptide comprises no more than six amino acid residues which have been exchanged, added or deleted as compared to GLP-1(7-37) (SEQ ID No. 1).

Claim [115] 117 (Currently Amended) A compound according to claim [113] 115, wherein said GLP-1 peptide comprises no more than 4 amino acid residues which are not encoded by the genetic code.

Claim [116] 118 (Currently Amended) A compound according to claim [109] 111, wherein said GLP-1 peptide is a DPPIV protected GLP-1 peptide.

Claim [117] 119 (Currently Amended) A compound according to claim [109] 111, wherein said compound is DPPIV stabilised.

Claim [118] 120 (Currently Amended) A compound according to claim [109] 111, wherein said GLP-1 peptide comprises an Aib residue in position 8.

Claim [119] 121 (Currently Amended) A compound according to claim [109] 111, wherein the amino acid residue in position 7 of said GLP-1 peptide is selected from the group consisting of D-histidine, desamino-histidine, 2-amino-histidine,  $\beta$ -hydroxy-histidine, homohistidine, N <sup>$\alpha$</sup> -acetyl-histidine,  $\alpha$ -fluoromethyl-histidine,  $\alpha$ -methyl-histidine, 3-pyridylalanine, 2-pyridylalanine and 4-pyridylalanine.

Claim [120] 122 (Currently Amended) A compound according to claim [109] 111, wherein said GLP-1 peptide is selected from the group consisting of Arg<sup>34</sup>GLP-1(7-37), Lys<sup>38</sup>Arg<sup>26,34</sup>GLP-1(7-38), Lys<sup>38</sup>Arg<sup>26,34</sup>GLP-1(7-38)-OH, Lys<sup>36</sup>Arg<sup>26,34</sup>GLP-1(7-36), Aib<sup>8,22,35</sup>GLP-1(7-37), Aib<sup>8,35</sup>GLP-1(7-37), Aib<sup>8,22</sup>GLP-1(7-37), Aib<sup>8,22,35</sup>Arg<sup>26,34</sup>Lys<sup>38</sup>GLP-1(7-38), Aib<sup>8,35</sup>Arg<sup>26,34</sup>Lys<sup>38</sup>GLP-1(7-38), Aib<sup>8,22</sup>Arg<sup>26,34</sup>Lys<sup>38</sup>GLP-1(7-38), Aib<sup>8,22,35</sup>Arg<sup>26,34</sup>Lys<sup>38</sup>GLP-1(7-38), Aib<sup>8,35</sup>Arg<sup>26,34</sup>Lys<sup>38</sup>GLP-1(7-38), Aib<sup>8,22,35</sup>Arg<sup>26</sup>Lys<sup>38</sup>GLP-1(7-38), Aib<sup>8,35</sup>Arg<sup>26</sup>Lys<sup>38</sup>GLP-1(7-38), Aib<sup>8,22</sup>Arg<sup>26</sup>Lys<sup>38</sup>GLP-1(7-38), Aib<sup>8,22,35</sup>Arg<sup>34</sup>Lys<sup>38</sup>GLP-1(7-38), Aib<sup>8,35</sup>Arg<sup>34</sup>Lys<sup>38</sup>GLP-1(7-38), Aib<sup>8,22</sup>Arg<sup>34</sup>Lys<sup>38</sup>GLP-1(7-38), Aib<sup>8,22,35</sup>Ala<sup>37</sup>Lys<sup>38</sup>GLP-1(7-38), Aib<sup>8,35</sup>Ala<sup>37</sup>Lys<sup>38</sup>GLP-1(7-38), Aib<sup>8,22</sup>Ala<sup>37</sup>Lys<sup>38</sup>GLP-1(7-38), Aib<sup>8,22,35</sup>Lys<sup>37</sup>GLP-1(7-37), Aib<sup>8,35</sup>Lys<sup>37</sup>GLP-1(7-37) and Aib<sup>8,22</sup>Lys<sup>37</sup>GLP-1(7-38).

Claim [121] 123 (Currently Amended) A compound according to claim [109] 111, wherein said GLP-1 peptide is attached to said hydrophilic spacer via the amino acid residue in position 23, 26, 34, 36 or 38 relative to the amino acid sequence SEQ ID No:1.

Claim [122] 124 (Currently Amended) A compound according to claim [109] 111, wherein said GLP-1 peptide is exendin-4.


Claim [123] 125 (Currently Amended) A compound according to claim [109] 111, wherein said GLP-1 peptide is HGEFTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPSKKKKKKK-amide.

Claim [124] 126 (Currently Amended) A compound according to claim [109] 111, wherein one albumin binding residue via said hydrophilic spacer is attached to the C-terminal amino acid residue of said GLP-1 peptide.


Claim [125] 127 (Currently Amended) A compound according to claim [124] 126, wherein a second albumin binding residue is attached to an amino acid residue which is not the C-terminal amino acid residue.

Claim [126] 128 (Currently Amended) A compound according to claim [73] 75, wherein said compound is selected from the group consisting of


$N^{\epsilon 37}$ -(2-(2-(2-(dodecylamino)ethoxy)ethoxy)acetyl)-[Aib<sup>8,22,35</sup>Lys<sup>37</sup>]GLP-1(7-37)amide




$N^{\epsilon 37}$ -(2-(2-(2-(17-sulphohexadecanoylamino)ethoxy)ethoxy)acetyl)-[Aib<sup>8,22,35</sup>,Lys<sup>37</sup>] GLP-1 (7-37)amide




$N^{\epsilon 37}$ -{2-[2-(2-(15-carboxypentadecanoylamino)ethoxy)ethoxy]acetyl}-[Aib<sup>8,22,35</sup>,Lys<sup>37</sup>] GLP-1(7-37)amide




N<sup>ε37</sup>-(2-(2-(2-(17-carboxyheptadecanoylamino)ethoxy)ethoxy)acetyl)[Aib<sup>8,22,35</sup>,Lys<sup>37</sup>]GLP-1(7-37)amide




N<sup>ε37</sup>-(2-(2-(2-(19-carboxynonadecanoylamino)ethoxy)ethoxy)acetyl)[Aib<sup>8,22,35</sup>,Lys<sup>37</sup>]GLP-1(7-37)amide




[Aib<sup>8,22,35</sup>,Arg<sup>26,34</sup>]GLP-1-(7-37)Lys(4-(Hexadecanoylamino)-4(S)-carboxybutyryl)-OH




[Aib<sup>8,22,35</sup>,Arg<sup>26,34</sup>]GLP-1-(7-37)Lys(2-(2-(2-(hexadecanoylamino)ethoxy)ethoxy)acetyl)-OH




N<sup>ε37</sup>(2-[2-(2,6-(S)-Bis-{2-[2-(2-(  
(dodecanoylamino)ethoxy)ethoxy]acetylamino}hexanoylamino)ethoxy]ethoxy}))  
acetyl-[Aib<sup>8,22,35</sup>]GLP-1(7-37)amide




N<sup>ε37</sup>-(2-[2-(2,6-(S)-Bis-{2-[2-(2-(  
(tetradecanoylamino)ethoxy)ethoxy]acetylamino}hexanoylamino)ethoxy]ethoxy}))  
acetyl-[Aib<sup>8,22,35</sup>]GLP-1(7-37)amide




[Aib<sup>8,22,35</sup>,Arg<sup>26,34</sup>]GLP-1-(7-37)Lys(2-(2-(2-(4-(Hexadecanoylamino)-4(S)-  
carboxybutyrylamino)ethoxy)ethoxy)acetyl)-OH



[Aib<sup>8,22,35</sup>]GLP-1(7-37)Lys((2-{2-[4-[4-(4-Amino-9,10-dioxo-3-sulfo-9,10-dihydro-anthracen-1-ylamino)-2-sulfo-phenylamino]-6-(2-sulfo-phenylamino)-[1,3,5]triazin-2-ylamino]-ethoxy}-ethoxy)-acetyl))amide




[Aib<sup>8,22,35</sup>]GLP-1(7-37)Lys(((2-[2-(2-{2-[2-(2-{2-[2-(15-carboxypentadecanoylamino)-ethoxy]ethoxy}acetyl amino)ethoxy]ethoxy}acetyl amino)ethoxy]ethoxy}acetyl))amide




N<sup>ε37</sup>-([2-(2-{3-[2,5-dioxo-3-(15-carboxypentadecylsulfanyl)-pyrrolidin-1-yl]-propionylamino}ethoxy)ethoxy)acetyl]-[D-Ala<sup>8</sup>,Lys<sup>37</sup>]-GLP-1-[7-




37]amide




[Aib<sup>8,22,35</sup>Ala<sup>37</sup>]GLP-1(7-37)Lys((2-(2-(2-(11-(oxalylamino)undecanoylamino)ethoxy)ethoxy)acetyl-  
)))amide




[Aib<sup>8,22,35</sup>,Ala<sup>37</sup>]-GLP-1(7-37)Lys({2-[2-(2-{2-[2-(2-(15-carboxy-pentadecanoylamino)-  
ethoxy]ethoxy}acetylamin)ethoxy]ethoxy}acetyl)amide




[Aib<sup>8,22,35</sup>,Ala<sup>37</sup>]-GLP-1(7-37)Lys((2-{2-[11-(5-Dimethylaminonaphthalene-1-  
sulfonylamino)undecanoylamino]ethoxy}ethoxy)acetyl)amide




[Aib<sup>8,22,35</sup>,Ala<sup>37</sup>]-GLP-1(7-37)Lys(((2-(2-{2-[1-(4-Chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl]acetyl}amino)ethoxy)ethoxy)acetyl))amide




[Aib<sup>8</sup>,Arg<sup>26,34</sup>,Glu<sup>22,23,30</sup>]GLP-1 H(7-37)Lys(2-(2-(2-(octadecanoylamino)ethoxy)ethoxy)acetyl)amide




[Aib<sup>8</sup>,Arg<sup>26,34</sup>,Glu<sup>22,23,30</sup>]GLP-1(7-37)Lys(2-(2-(2-(eicosanoylamino)ethoxy)ethoxy)acetyl)amide




[Gly<sup>8</sup>,Arg<sup>26,34</sup>] GLP-1 H-(7-37)Lys(2-(2-(2-(2-(2-(2-(4-(octadecanoylamino)-4(S)-carboxybutyrylamino)ethoxy)ethoxy)acetyl)ethoxy)ethoxy)acetyl)-OH




[Aib<sup>8</sup>,Arg<sup>26,34</sup>]GLP-1 (7-37)Lys{2-(2-(2-(2-[2-(2-(octadecanoylamino)ethoxy)ethoxy]acetyl)ethoxy)ethoxy)acetyl)}-OH




[Aib<sup>8</sup>] -GLP-1-(7-37)Lys (2-(2-(2-(4-(Hexadecanoylamino)-4(S)-carboxybutyrylamino)ethoxy)ethoxy)acetyl)-OH




[Aib<sup>8</sup>,Arg<sup>26,34</sup>] GLP-1(7-37) Lys{2-(2-(2-(2-[2-(2-(4-(octadecanoylamino)-4-carboxybutyrylamino)ethoxy)ethoxy]acetyl)ethoxy)ethoxy)acetyl)}-OH




[Aib<sup>8</sup>,Arg<sup>26,34</sup>] GLP-1 (7-37)Lys{2-(2-(2-(2-[2-(2-(17-carboxyheptanoylamino)ethoxy)ethoxy]acetyl)ethoxy)ethoxy)acetyl)}-OH




[Gly<sup>8</sup>, Arg<sup>26,34</sup>] GLP1-(7-37) Lys{2-(2-(2-(2-[2-(2-(17-carboxyheptadecanoylamino)ethoxy)ethoxy]acetyl)ethoxy)ethoxy)acetyl)}-OH




[Aib<sup>8</sup>]GLP-1-(7-37)Lys(2-(2-(2-(2-(2-(2-(4-(Hexadecanoylamino)-4(S)-carboxybutyrylamino)ethoxy)ethoxy)acetyl)ethoxy)ethoxy)acetyl)-OH




N<sup>ε37</sup>-(2-(2-(2-(dodecanoylamino)ethoxy)ethoxy)acetyl)-[Aib<sup>8,22,35</sup>Lys<sup>37</sup>] GLP-1 H(7-37)-amide




N<sup>ε37</sup>-(2-(2-(2-(tetradecanoylamino)ethoxy)ethoxy)acetyl)-[Aib<sup>8,22,35</sup>Lys<sup>37</sup>] GLP-1 H(7-37)-amide




N<sup>ε37</sup>-(2-(2-(2-(hexadecanoylamino)ethoxy)ethoxy)acetyl)-[Aib<sup>8,22,35</sup>Lys<sup>37</sup>] GLP-1 (7-37)-amide




N<sup>ε37</sup>-(2-(2-(2-(octadecanoylamino)ethoxy)ethoxy)acetyl)-[Aib<sup>8,22,35</sup>Lys<sup>37</sup>] GLP-1 (7-37)-amide




$N^{\epsilon 37}$ -(2-(2-(2-(eicosanoylamino)ethoxy)ethoxy)acetyl)-[Aib<sup>8,22,35</sup>Lys<sup>37</sup>] GLP-1(7-37)-amide




$N^{\epsilon 36}$ -(2-(2-(2-(2-(2-(2-(octadecanoylamino)ethoxy)ethoxy)acetylaminomethoxy)ethoxy)ethoxy)ethoxy)acetyl)-[Aib<sup>8</sup>,Arg<sup>26,34</sup>,Lys<sup>36</sup>]GLP-1-(7-37)-OH




$N^{\epsilon 36}$ -(2-(2-(2-(2-(2-(2-(octadecanoylamino)ethoxy)ethoxy)acetylaminomethoxy)ethoxy)ethoxy)ethoxy)acetyl)-[Arg<sup>26,34</sup>,Lys<sup>36</sup>]GLP-1(7-37)-OH




N<sup>ε36</sup>-{2-(2-(2-(2-[2-(2-(octadecanoylamino)ethoxy)ethoxy]acetylamino)ethoxy)ethoxy)acetyl)}-[Gly<sup>8</sup>,Arg<sup>26,34</sup>,Lys<sup>36</sup>]GLP-1-(7-37)-OH



N<sup>ε37</sup>-(2-(2-(2-(4-(4,4,5,5,6,6,7,7,8,8,9,9,9-tridecafluorononanoylsulfamoyl)butyrylamino)ethoxy)ethoxy)acetyl))[Aib<sup>8,22,35</sup>,Lys<sup>37</sup>] GLP-1-(7-37)-OH



N<sup>ε37</sup>-(2-(2-(2-(3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,11,11,12,12,12-Heneicosafuoro-dodecyloxyacetylamino)ethoxy)ethoxy)acetyl))[Aib<sup>8,22,35</sup>,Lys<sup>37</sup>]GLP-1-(7-37)-OH



N<sup>ε37</sup>-(2-(2-(2-(4-(hexadecanoylsulfamoyl)butyrylamino)ethoxy)ethoxy)acetyl))[Aib<sup>8,22,35</sup>,Lys<sup>37</sup>] GLP-1-(7-37)-OH







,

,


$\text{N}^{\epsilon 20}\{2-(2-(2-(2-[2-(2-(4-(\text{hexadecanoylamino})-4\text{-carboxybutyrylamino)ethoxy)ethoxy]acetylamino)ethoxy)ethoxy)acetyl)\}-\text{exendin}(1-39)$




[Ala<sup>8</sup>, Arg<sup>26,34</sup>]GLP-1(7-37)Lys((2-[2-((2-oxalylamino-3-carboxy-2-4,5,6,7-tetrahydro-benzo[b]thiophen-6-yl-acetylamino))ethoxy]ethoxyacetyl) amide




[Aib<sup>8,22,35</sup>]GLP-1(7-37)Lys((2-[2-((2-oxalylamino-3-carboxy-2-4,5,6,7-tetrahydro-benzo[b]thiophen-6-yl-acetylamino))ethoxy]ethoxyacetyl) amide




N<sup>ε36</sup>-(2-(2-(2-(2-(2-(2-(4-(octadecanoylamino)-4(S)-carboxybutyrylamino)ethoxy)ethoxy)acetylamino)ethoxy)ethoxy)acetyl)-[Aib<sup>8</sup>, Arg<sup>26,34</sup>, Lys<sup>36</sup>]GLP-1-(7-37)-OH




N<sup>ε36</sup>-(2-(2-(2-(2-(2-(2-(4-(octadecanoylamino)-4(S)-carboxybutyrylamino)ethoxy)ethoxy)acetyl)amino)ethoxy)ethoxy)acetyl)-[Gly<sup>8</sup>,Arg<sup>26,34</sup>,Lys<sup>36</sup>]GLP-1-(7-37)-OH




N<sup>ε37</sup>-2-(2-(2-(4-(4-(Heptadecanoylamino)-4-(S)-carboxybutyrylamino)-4-(S)-carboxybutyrylamino)ethoxy)ethoxy)acetyl-[Aib<sup>8,22,35</sup>,Lys<sup>37</sup>]GLP-1-(7-37)-NH<sub>2</sub>




N<sup>ε37</sup>-2-(2-[2-(2-[2-(4-[4-(Heptadecanoylamino)-4-(S)-  
carboxybutyrylamino]-4-(S)-carboxybutyrylamino)ethoxy]  
ethoxy)acetylamin)ethoxy]ethoxy)acetyl-[Aib<sup>8,22,35</sup>,Lys<sup>37</sup>]GLP-1-(7-37)-NH<sub>2</sub>




N<sup>ε26</sup>-(2-(2-(2-(4-(Hexadecanoylamino)-4(S)-carboxybutyrylamino)  
ethoxy)ethoxy)acetyl)-[Aib<sup>8</sup>,Arg<sup>34</sup>]GLP-1-(7-37)-  
-OH




N<sup>ε26</sup>-2-(2-2-(2-(2-(2-(4-(Octadecanoylamino)-4(S)-  
carboxybutyrylamino)ethoxy)ethoxy)acetylamin)ethoxy)ethoxy)acetyl-  
[Aib<sup>8</sup>, Arg<sup>34</sup>]GLP-1-(7-37)-OH




[Gly<sup>8</sup>,Arg<sup>26,34</sup>]GLP-1(7-37)Lys(2-(2-(19-(carboxy)nonadecanoylamino)ethoxy)ethoxy)acetyl)-OH




[Gly<sup>8</sup>,Arg<sup>26,34</sup>]GLP-1(7-37)Lys((2-(2-(17-(carboxy)heptadecanoylamino)ethoxy)ethoxy)acetyl))-OH




[Gly<sup>8</sup>,Arg<sup>26,34</sup>]GLP-1(7-37)Lys(2-(2-(2-(4-(19-(carboxy)nonadecanoylamino)-4-carboxybutyrylamino)ethoxy)ethoxy)acetyl))-OH




[Gly<sup>8</sup>,Arg<sup>26,34</sup>]GLP-1(7-37)Lys((2-(2-(2-(2-(2-(2-(2-(2-(hexadecanoylamino)ethoxy)ethoxy)acetyl)ethoxy)ethoxy)acetyl)ethoxy)ethoxy)-acetyl))-OH




[Gly<sup>8</sup>,Arg<sup>26,34</sup>]GLP-1 (7-37)Lys (2-(2-(2-(2-(2-(2-(octadecanoylamino)ethoxy)ethoxy)-acetyl)ethoxy)ethoxy)acetyl) NH<sub>2</sub>



N<sup>ε20</sup>-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(4-(17-(carboxy)heptadecanoylamino)-4-carboxybutyrylamino)ethoxy)ethoxy)acetylamino)ethoxy)ethoxy)acetylamino)ethoxy)ethoxy)acetylamino)ethoxy)ethoxy)acetyl) [Lys<sup>20</sup>]exendin-4 (1-39)-NH<sub>2</sub>




N<sup>ε36</sup>-(2-(2-(2-(2-(2-(2-(17-Carboxyheptadecanoylamino)ethoxy)ethoxy)acetylamino)ethoxy)ethoxy)acetyl) [Aib<sup>8</sup>, Arg<sup>26,34</sup>, Lys<sup>36</sup>] GLP-1 (7-37)




N<sup>ε36</sup>-(2-(2-(2-(2-(2-(2-(17-Carboxyheptadecanoylamino)ethoxy)ethoxy)acetylamino)ethoxy)ethoxy)acetyl) [Arg<sup>26,34</sup>, Lys<sup>36</sup>] GLP-1 (7-37)









N<sup>ε36</sup>-(2-(2-(2-(2-(2-(4-(octadecanoylamino)-4(S)-carboxybutyrylamino)ethoxy)ethoxy)acetylamino)ethoxy)ethoxy)acetyl)-[Arg<sup>26,34</sup>,Lys<sup>36</sup>]GLP-1-(7-37)




N<sup>ε26</sup>-(2-[2-(2-[2-(2-[2-(17-Carboxyheptadecanoylamino)ethoxy]ethoxy)acetylamino]ethoxy)ethoxy]acetyl)-[Arg<sup>34</sup>]GLP-1-(7-37)-OH




N<sup>ε26</sup>-[2-(2-[2-(2-[2-(2-[4-(17-Carboxyheptadecanoylamino)-4(S)-carboxybutyrylamino]ethoxy)ethoxy]acetylamino)ethoxy]ethoxy)acetyl][Arg<sup>34</sup>]GLP-1-(7-37)-OH



N<sup>ε20</sup>-(2-(2-(2-(2-(2-(2-(2-(2-(17-Carboxyheptadecanoylamino)ethoxy)ethoxy)acetylamino)ethoxy)ethoxy)acetyl-amino)ethoxy)ethoxy)acetyl)[Lys<sup>20</sup>] Exendin-4 (1-39) amide




[Gly<sup>8</sup>, Glu<sup>22,23,30</sup>, Arg<sup>18,26,34</sup>]GLP1 (7-37) Lys(2-(2-(2-(2-(2-(2-(17-carboxyheptadecanoylamino)ethoxy)ethoxy)acetylamino)ethoxy))ethoxy)acetyl)-NH<sub>2</sub>



[illegible][illegible]

[3-(5-Imidazolyl)propionyl<sup>7</sup>, Aib<sup>8</sup>, Arg<sup>26,34</sup> ] GLP-1 (7-37)Lys{2-(2-(2-(2-[2-(2-(17-carboxyheptanoylamino)ethoxy)ethoxy]acetylamino)ethoxy)ethoxy)acetyl)}-OH



Claim [127] 129 (Currently Amended) A compound according to claim [73] 75, wherein said therapeutic polypeptide is a glucagon-like peptide 2 (GLP-2) peptide.

Claim [128] 130 (Currently Amended) A compound according to claim [127] 129, wherein said GLP-2 peptide is a DPPIV-protected GLP-2 peptide.

Claim [129] 131 (Currently Amended) A compound according to claim [127] 129, wherein said GLP-2 peptide is Gly<sup>2</sup>-GLP-2(1-33).

Claim [130] 132 (Currently Amended) A compound according to claim [127] 129, wherein said GLP-2 peptide is Lys<sup>17</sup>Arg<sup>30</sup>-GLP-2(1-33).

Claim [131] 133 (Currently Amended) A compound according to claim [73] 75, wherein said therapeutic polypeptide is human insulin or an analogue thereof.

Claim [132] 134 (Currently Amended) A compound according to claim [131] 133, wherein said therapeutic polypeptide is selected from the group consisting of Asp<sup>B28</sup>-human insulin, Lys<sup>B28</sup>,Pro<sup>B29</sup>-human insulin, Lys<sup>B3</sup>,Glu<sup>B29</sup>-human insulin, Gly<sup>A21</sup>,Arg<sup>B31</sup>,Arg<sup>B32</sup>-human insulin and des(B30) human insulin.

Claim [133] 135 (Currently Amended) A compound according to claim [73] 75, wherein said therapeutic polypeptide is human growth hormone or an analogue thereof.

Claim [134] 136 (Currently Amended) A compound according to claim [73] 75, wherein said therapeutic polypeptide is parathyroid hormone or an analogue thereof.

Claim [135] 137 (Currently Amended) A compound according to claims [73] 75, wherein said therapeutic polypeptide is human follicle stimulating hormone or an analogue thereof.

Claim [136] 138 (Currently Amended) A compound according to claim [73] 75, wherein said therapeutic polypeptide has a molar weight of less than 100 kDa.

Claim [137] 139 (Currently Amended) A compound according to claim [73] 75, wherein said therapeutic polypeptide is selected from the group consisting of a growth factor, a somatomedin, interferon, pro-urokinase, urokinase, tissue plasminogen activator (t-PA), plasminogen activator inhibitor 1, plasminogen activator inhibitor 2, von Willebrandt factor, a cytokine, a colony stimulating factor (CFS), a stem cell factor, a tumor necrosis factor, a protease inhibitor, an opioid, a hormone, a neuropeptide, and a melanocortin.

Claim [138] 140 (Currently Amended) A pharmaceutical composition comprising a compound according to claim [73] 75 and a pharmaceutically acceptable excipient.

Claim [139] 141 (Currently Amended) The pharmaceutical composition according to claim [138] 140, which is suited for parenteral administration.

Claim [140] 142 (Currently Amended) A method for treating hyperglycemia, type 2 diabetes, impaired glucose tolerance, type 1 diabetes, obesity, hypertension, syndrome X, dyslipidemia, cognitive disorders, atherosclerosis, myocardial infarction, coronary heart disease and other cardiovascular disorders, stroke, inflammatory bowel syndrome, dyspepsia or gastric ulcers, said

method comprising administering to a subject in need of such treatment an effective amount of a compound according to claim [109] 111.

Claim [141] 143 (Currently Amended) A method for delaying or preventing disease progression in type 2 diabetes in a subject, said method comprising administering to said subject an effective amount of a compound according to claim [109] 111.

Claim [142] 144 (Currently Amended) A method for decreasing food intake, decreasing  $\beta$ -cell apoptosis, increasing  $\beta$ -cell function and  $\beta$ -cell mass, and/or for restoring glucose sensitivity to  $\beta$ -cells in a subject, said method comprising administering to said subject an effective amount of a compound according to claim [109] 111.

Claim [143] 145 (Currently Amended) A method for treating small bowel syndrome, inflammatory bowel syndrome or Crohns disease, said method comprising administering to a subject in need of such treatment an effective amount of a compound according to claim [127] 129.

Claim [144] 146 (Currently Amended) A method for treating hyperglycemia, type 1 diabetes, type 2 diabetes or  $\beta$ -cell deficiency, said method comprising administering to a subject in need of such treatment an effective amount of a compound according to claim [131] 133.